PE20161323A1 - Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos - Google Patents

Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos

Info

Publication number
PE20161323A1
PE20161323A1 PE2016001101A PE2016001101A PE20161323A1 PE 20161323 A1 PE20161323 A1 PE 20161323A1 PE 2016001101 A PE2016001101 A PE 2016001101A PE 2016001101 A PE2016001101 A PE 2016001101A PE 20161323 A1 PE20161323 A1 PE 20161323A1
Authority
PE
Peru
Prior art keywords
optionally substituted
compositions
methods
alkyl
treatment
Prior art date
Application number
PE2016001101A
Other languages
English (en)
Inventor
Matthew W Cartwright
Yun-Xing Cheng
Christine Edwards
Simon C Goodacre
Mark E Zak
Snahel Patel
Nicholas C Ray
Mohammed Sajad
Po-Wai Yuen
Wei Li
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20161323A1 publication Critical patent/PE20161323A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a compuestos derivados de triazolopiridina de formula (0), sales y estereoisomeros de los mismos donde Ar1 es fenileno o heteroarileno de 3 a 11 miembros, opcionalmente sustituido; X es -O- o –N(R1b)-(CRx1Ry1)p-; Rx1 y Ry1 son H o alquilo C1-C6; R1a es H, alquilo C1-C6, opcionalmente sustituido, entre otros; R1b es H, cicloalquilo C3-C8, opcionalmente sustituido, entre otros; R2 es heterociclilo de 3-11 miembros que contiene al menos un N, (a), entre otros; R3, R4 y R5 son H, CH3, entre otros; R6 y R7 son H, halogeno, entre otros o forman un fenilo o heterociclilo de 3 a 11 miembros opcionalmente sustituido; m1 y m2 son 0,1 o 2; n es 0 o 1 y p es 0 a 6. Tambien se refiere a una composicion y un metodo de diagnostico o tratamiento. Dichos compuestos inhiben la actividad de la proteina citoplasmatica Janus cinasa siendo utiles en el tratamiento de enfermedades inflamatorias como el asma
PE2016001101A 2013-09-05 2014-08-27 Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos PE20161323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361874038P 2013-09-05 2013-09-05

Publications (1)

Publication Number Publication Date
PE20161323A1 true PE20161323A1 (es) 2016-11-25

Family

ID=52627792

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001101A PE20161323A1 (es) 2013-09-05 2014-08-27 Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos

Country Status (17)

Country Link
US (4) US20160185780A1 (es)
EP (1) EP3041841B1 (es)
JP (1) JP6472803B2 (es)
KR (1) KR20160050080A (es)
CN (1) CN105745209B (es)
AU (1) AU2014317600A1 (es)
CA (1) CA2922770A1 (es)
CL (1) CL2016000496A1 (es)
CR (1) CR20160070A (es)
EA (1) EA201690523A1 (es)
IL (1) IL244066A0 (es)
MA (1) MA38884A1 (es)
MX (1) MX2016002764A (es)
PE (1) PE20161323A1 (es)
PH (1) PH12016500347A1 (es)
SG (1) SG11201601707PA (es)
WO (1) WO2015032286A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265464A1 (en) * 2015-03-04 2018-01-10 F. Hoffmann-La Roche AG Triazolopyridine compounds and methods of use thereof
EP3390402B1 (en) * 2015-12-18 2020-01-15 H. Hoffnabb-La Roche Ag Therapeutic compounds, compositions and methods of use thereof
JP6832342B2 (ja) * 2016-03-31 2021-02-24 武田薬品工業株式会社 複素環化合物
RU2019109570A (ru) 2016-09-06 2020-10-08 Ф. Хоффманн-Ля Рош Аг 8-(азетидин-1-ил)-[1,2,4]триазоло[1,5-а]пиридинилы, композиции и способы их применения
CN109400610A (zh) * 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
US20240158386A1 (en) * 2021-03-02 2024-05-16 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
TW202334136A (zh) * 2021-11-03 2023-09-01 美商傳達治療有限公司 PI3Kα抑制劑及其製造與使用方法
US11746108B1 (en) * 2022-06-13 2023-09-05 Apm Therapeutics 1, Inc. Triazolopyridine polymorph A

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US6693116B2 (en) 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2009259867A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
PE20110545A1 (es) * 2008-06-20 2011-08-18 Genentech Inc Compuestos de triazolopiridina como inhibidores de jak
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
CA2763900A1 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
KR20130091464A (ko) * 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체

Also Published As

Publication number Publication date
EP3041841A4 (en) 2017-04-19
IL244066A0 (en) 2016-04-21
SG11201601707PA (en) 2016-04-28
KR20160050080A (ko) 2016-05-10
WO2015032286A1 (en) 2015-03-12
EP3041841A1 (en) 2016-07-13
JP2016529299A (ja) 2016-09-23
CR20160070A (es) 2016-04-01
US9873709B2 (en) 2018-01-23
CN105745209B (zh) 2018-10-23
AU2014317600A1 (en) 2016-03-03
CN105745209A (zh) 2016-07-06
MA38884A1 (fr) 2017-06-30
EA201690523A1 (ru) 2016-07-29
EP3041841B1 (en) 2019-06-05
CL2016000496A1 (es) 2016-10-07
MX2016002764A (es) 2016-05-26
JP6472803B2 (ja) 2019-02-20
US20160185780A1 (en) 2016-06-30
US20180298033A1 (en) 2018-10-18
CA2922770A1 (en) 2015-03-12
US20190233441A1 (en) 2019-08-01
US20170226132A1 (en) 2017-08-10
PH12016500347A1 (en) 2016-05-16

Similar Documents

Publication Publication Date Title
PE20161323A1 (es) Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
SV2016005229A (es) Inhibidores de syk
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ECSP16071151A (es) Inhibidores de dihidropirrolopiridina de ror-gamma
CR20140091A (es) Nuevos derivados dihidroquinolina-2-ona
ECSP14013264A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
UY36101A (es) Herbicidas de piridazinona
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
CR20190156A (es) Derivados de bipirazol como inhibidores jak
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
UY37205A (es) Inhibidores de bromodominios
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
PE20121695A1 (es) 5-alquinil-pirimidinas
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20140135A (es) Nuevos derivados de aril-quinolina
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
ECSP16074478A (es) Compuestos novedosos
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas

Legal Events

Date Code Title Description
FD Application declared void or lapsed